An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.

Trial Profile

An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs CYAD 01 (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms DEPLETHINK
  • Sponsors Celyad
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Jun 2018 Planned End Date changed from 3 Aug 2034 to 1 Aug 2021.
    • 05 Jun 2018 Planned primary completion date changed from 3 Aug 2021 to 1 Aug 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top